Ligand Pharmaceuticals (LGND) Revenue (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Revenue of $51.7 million for Q1 2026, down 13.31% sequentially from $59.7 million in Q4 2025, and up 14.09% YoY from $45.3 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Revenue (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Revenue for 17 years, with the latest figure at $51.7 million in Q1 2026.
- Quarterly Revenue rose 14.09% year-over-year to $51.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $274.5 million (up 51.24% YoY) and the FY2025 annual result came in at $268.1 million, up 60.4% from the prior year.
- Revenue retreated to $51.7 million in Q1 2026 per LGND's latest filing, from $59.7 million in the prior quarter.
- Over five years, Revenue peaked at $115.5 million in Q3 2025 and troughed at $26.4 million in Q2 2023.
- A 5-year average of $47.9 million and a median of $45.3 million in 2025 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2025: Revenue tumbled 47.4% in 2023, then jumped 122.85% in 2025.
- Over 5 years, Revenue stood at $50.4 million in 2022, then sank by 44.22% to $28.1 million in 2023, then soared by 52.35% to $42.8 million in 2024, then soared by 39.37% to $59.7 million in 2025, then fell by 13.31% to $51.7 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $51.7 million, $59.7 million, and $115.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 63.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.69 Mn |
| Mar 31, 2026 | 51.72 Mn |
| Dec 31, 2025 | 59.67 Mn |
| Sep 30, 2025 | 115.46 Mn |
| Jun 30, 2025 | 47.63 Mn |
| Mar 31, 2025 | 45.33 Mn |
| Dec 31, 2024 | 42.81 Mn |
| Sep 30, 2024 | 51.81 Mn |
| Jun 30, 2024 | 41.53 Mn |
| Mar 31, 2024 | 30.98 Mn |
| Dec 31, 2023 | 28.10 Mn |
| Sep 30, 2023 | 32.87 Mn |
| Jun 30, 2023 | 26.37 Mn |
| Mar 31, 2023 | 43.98 Mn |
| Dec 31, 2022 | 50.38 Mn |
| Sep 30, 2022 | 59.22 Mn |
| Jun 30, 2022 | 50.13 Mn |
| Mar 31, 2022 | 36.52 Mn |
| Dec 31, 2021 | 56.40 Mn |
| Sep 30, 2021 | 59.69 Mn |